Kiniksa Pharmaceuticals International (KNSA) Other Accumulated Expenses (2017 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has 10 years of Other Accumulated Expenses data on file, last reported at $20.1 million in Q2 2026.

• Quarterly Other Accumulated Expenses rose 11.39% year-over-year to $20.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $20.1 million (up 11.39% YoY) and the FY2025 annual result came in at $22.1 million, up 29.85% from the prior year.
• Other Accumulated Expenses retreated to $20.1 million in Q2 2026, from $20.7 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $22.2 million in Q1 2022 to a low of $4.3 million in Q1 2023.
• A 5-year average of $14.5 million and a median of $15.2 million in 2022 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Other Accumulated Expenses plunged 80.49% — and 2024, when it surged 163.66%.
• Tracing KNSA's Other Accumulated Expenses over 5 years: stood at $8.4 million in 2022, then declined by 2.21% to $8.2 million in 2023, then soared by 108.06% to $17.0 million in 2024, then increased by 29.85% to $22.1 million in 2025, then retreated by 9.41% to $20.1 million in 2026.
• The last three Other Accumulated Expenses figures came in at $20.1 million (Q2 2026), $20.7 million (Q1 2026), and $22.1 million (Q4 2025), per Business Quant data.